The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Osteoporosis in men with prostate carcinoma receiving androgen‐deprivation therapy: Recommendations for diagnosis and therapies
Abstract
BACKGROUND: Androgen‐deprivation therapy (ADT) is prescribed with increasing frequency for men with prostate carcinoma. There is growing concern about the effects of such therapy on the skeleton. In the current review, the authors addressed the current research, diagnostic methods, and treatment recommendations for bone loss and osteoporosis in men with prostate carcinoma who received ADT. METHODS: Data were obtained from electronic literature searches (for the years 1986 through 2002) and from abstracts and meeting proceedings. All randomized and nonrandomized clinical trials, retrospective studies, and cross‐sectional studies of osteoporosis in men with prostate carcinoma who received ADT with or without other therapies were reviewed. RESULTS: The findings confirmed that ADT resulted in significant bone loss in men with prostate carcinoma. Bone mineral density (BMD) of the hip, as measured by dual‐energy X‐ray absorptiometry (DXA), is considered the preferred site of assessment in older men. Spinal BMD is equally important, although careful interpretation of spinal DXA values is required, because of coexisting facet joint disease and extravertebral calcification. Osteoporosis is diagnosed when BMD is > 2.5 standard deviations below a reference mean. Men with prostate carcinoma who were treated with ADT had average BMD measurements below those of eugonadal men. Rates of bone loss ranged from 2% to 8% in the lumbar spine and from 1.8% to 6.5% in the femoral neck during the initial 12 months of continuous ADT. Retrospective data indicated an increased risk of fracture in men with prostate carcinoma who were treated with ADT. CONCLUSIONS: For men with prostate carcinoma who are at high risk for osteoporosis and fractures, clinical management should be dictated by the results of radiographic and DXA skeletal assessment. Cancer 2004;100:892–9. © 2004 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vertebral fracture assessment using a semiquantitative technique
Genant, H. K., Wu, C. Y., van Kuijk, C., & Nevitt, M. C. (1993) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650080915 · Cited by 3,691
Greenlee, R. T., Hill-Harmon, M. B., Murray, T., & Thun, M. (2001) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.51.1.15 · Cited by 3,288
ASSESSMENT OF FRACTURE RISK AND ITS APPLICATION TO SCREENING FOR POSTMENOPAUSAL OSTEOPOROSIS
Alexeeva, L. P., Burkhardt, P., Christiansen, C., Cooper, C. C., Delmas, P. D., Johnell, O., Johnston, C. C., Kanis, J. A., Lips, P. T. A. M., Melton, L. J., et al. (1994) · Cited by 2,655
Saad, F., Gleason, D. M., Murray, R., Tchekmedyian, S., Venner, P., Lacombe, L., Chin, J. L., Vinholes, J. J., Goas, J. A., & Chen, B. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.19.1458 · Cited by 1,656
Bolla, M., Gonzalez, D., Warde, P., Dubois, J. B., Mirimanoff, R.-O., Storme, G., Bernier, J., Kuten, A., Sternberg, C., Gil, T., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199707313370502 · Cited by 1,548
Alendronate for the Treatment of Osteoporosis in Men
Orwoll, E., Ettinger, M., Weiss, S., Miller, P., Kendler, D., Graham, J., Adami, S., Weber, K., Lorenc, R., Pietschmann, P., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200008313430902 · Cited by 973
The crippling consequences of fractures and their impact on quality of life
Cooper, C. (1997) · The American Journal of Medicine · doi:10.1016/s0002-9343(97)90022-x · Cited by 699
Pamidronate to Prevent Bone Loss during Androgen-Deprivation Therapy for Prostate Cancer
Smith, M. R., McGovern, F. J., Zietman, A. L., Fallon, M. A., Hayden, D. L., Schoenfeld, D. A., Kantoff, P. W., & Finkelstein, J. S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010845 · Cited by 696
Self-citationBone Density and Fracture Risk in Men
Dr. Melton, L. J., Atkinson, E. J., O'Connor, M. K., O'Fallon, W. M., & Riggs, B. L. (1998) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1998.13.12.1915 · Cited by 684
SMITH, M. R., EASTHAM, J., GLEASON, D. M., SHASHA, D., TCHEKMEDYIAN, S., & ZINNER, N. (2003) · Journal of Urology · doi:10.1097/01.ju.0000063820.94994.95 · Cited by 650
Self-citationPROGRESSIVE OSTEOPOROSIS DURING ANDROGEN DEPRIVATION THERAPY FOR PROSTATE CANCER
DANIELL, H. W., DUNN, S. R., FERGUSON, D. W., LOMAS, G., NIAZI, Z., & STRATTE, P. T. (2000) · Journal of Urology · doi:10.1016/s0022-5347(05)68000-7 · Cited by 452
Jones, G., Nguyen, T., Sambrook, P., Kelly, P. J., & Eisman, J. A. (1994) · BMJ · doi:10.1136/bmj.309.6956.691 · Cited by 451
Khosla, S. (1998) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.83.7.2266 · Cited by 447
ŠTĚPÁN, J. J., LACHMAN, M., ZVĚŘINA, J., PACOVSKÝ, V., & BAYLINK, D. J. (1989) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-69-3-523 · Cited by 424
RE: OSTEOPOROSIS AFTER ORCHIECTOMY FOR PROSTATE CANCER
Krongrad, A., Levis, S., & Roos, B. A. (1997) · Journal of Urology · doi:10.1016/s0022-5347(01)64271-x · Cited by 339
Hip Fracture Prediction in Elderly Men and Women: Validation in the Rotterdam Study
De Laet, C. E. D. H., Van Hout, B. A., Burger, H., Weel, A. E. A. M., Hofman, A., & Pols, H. A. P. (1998) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1998.13.10.1587 · Cited by 331
BERRUTI, A., DOGLIOTTI, L., TERRONE, C., CERUTTI, S., ISAIA, G., TARABUZZI, R., REIMONDO, G., MARI, M., ARDISSONE, P., DE LUCA, S., et al. (2002) · Journal of Urology · doi:10.1016/s0022-5347(05)64985-3 · Cited by 315
Osteoporosis After Orchiectomy for Prostate Cancer
Daniell, H. W. (1997) · Journal of Urology · doi:10.1016/s0022-5347(01)65165-6 · Cited by 315
MAILLEFERT, J. F., SIBILIA, J., MICHEL, F., SAUSSINE, C., JAVIER, R. M., & TAVERNIER, C. (1999) · Journal of Urology · doi:10.1016/s0022-5347(01)61639-2 · Cited by 308
Bone Loss following Hypogonadism in Men with Prostate Cancer Treated with GnRH Analogs
Mittan, D. (2002) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.8.3656 · Cited by 278
Townsend, M. F., Sanders, W. H., Northway, R. O., & Graham, S. D. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19970201)79:3<545::aid-cncr17>3.0.co;2-3 · Cited by 260
Diamond, T., Campbell, J., Bryant, C., & Lynch, W. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19981015)83:8<1561::aid-cncr11>3.0.co;2-z · Cited by 246
Self-citationBisphosphonates: Pharmacology, Mechanisms of Action and Clinical Uses
Russell, R. G. G., Croucher, P. I., & Rogers, M. J. (1999) · Osteoporosis International · doi:10.1007/pl00004164 · Cited by 240
Markers of bone turnover for the management of patients with bone metastases from prostate cancer
Garnero, P., Buchs, N., Zekri, J., Rizzoli, R., Coleman, R. E., & Delmas, P. D. (2000) · British Journal of Cancer · doi:10.1054/bjoc.1999.1012 · Cited by 238
Bone Histomorphometry in Hypogonadal and Eugonadal Men with Spinal Osteoporosis*
JACKSON, J. A., KLEEREKOPER, M., PARFITT, M., RAO, D. S., VILLANUEVA, A. R., & FRAME, B. (1987) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-65-1-53 · Cited by 199
Gender Specificity in the Genetic Determinants of Peak Bone Mass
Orwoll, E. S., Belknap, J. K., & Klein, R. F. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.11.1962 · Cited by 194
Diamond, T. H., Winters, J., Smith, A., De Souza, P., Kersley, J. H., Lynch, W. J., & Bryant, C. (2001) · Cancer · doi:10.1002/1097-0142(20010915)92:6<1444::aid-cncr1468>3.0.co;2-m · Cited by 190
Self-citationOEFELEIN, M. G., RICCHUITI, V., CONRAD, W., SEFTEL, A., BODNER, D., GOLDMAN, H., & RESNICK, M. (2001) · Journal of Urology · doi:10.1016/s0022-5347(05)65661-3 · Cited by 188
Bone Loss in Men with Prostate Cancer Treated with Gonadotropin-Releasing Hormone Agonists1
Stoch, S. A., Parker, R. A., Chen, L., Bubley, G., Ko, Y.-J., Vincelette, A., & Greenspan, S. L. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.6.7558 · Cited by 186
Kiratli, B. J., Srinivas, S., Perkash, I., & Terris, M. K. (2001) · Urology · doi:10.1016/s0090-4295(00)00895-5 · Cited by 172
Androgen deprivation therapy for prostate cancer results in significant loss of bone density
Wei, J. T., Gross, M., Jaffe, C. A., Gravlin, K., Lahaie, M., Faerber, G. J., & Cooney, K. A. (1999) · Urology · doi:10.1016/s0090-4295(99)00301-5 · Cited by 169
What Is the Role of Serial Bone Mineral Density Measurements in Patient Management?
Lenchik, L., Kiebzak, G. M., & Blunt, B. A. (2002) · Journal of Clinical Densitometry · doi:10.1385/jcd:5:3s:s29 · Cited by 168
Marcus, R., Wong, M., Heath, H., & Stock, J. L. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.1.0453 · Cited by 164
Hatano, T., Oishi, Y., Furuta, A., Iwamuro, S., & Tashiro, K. (2000) · British Journal of Urology · doi:10.1046/j.1464-410x.2000.00774.x · Cited by 152
Bone Loss in Men with Prostate Cancer Treated with Gonadotropin-Releasing Hormone Agonists
Stoch, S. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.6.2787 · Cited by 150
Pathogenesis of Vertebral Crush Fractures in Men
BAILLIE, S. P., DAVISON, C. E., JOHNSON, F. J., & Francis, R. M. (1992) · Age and Ageing · doi:10.1093/ageing/21.2.139 · Cited by 139
Binkley, N., Schmeer, P., Wasnich, R. D., & Lenchik, L. (2002) · Journal of Clinical Densitometry · doi:10.1385/jcd:5:3s:s19 · Cited by 139
Ringe, J. D., Faber, H., & Dorst, A. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.11.7988 · Cited by 137
Fracture Risk Following Bilateral Orchiectomy
Melton, L. J., Alothman, K. I., Khosla, S., Achenbach, S. J., Oberg, A. L., & Zincke, H. (2003) · The Journal of Urology · doi:10.1097/01.ju.0000059281.67667.97 · Cited by 136
Hip fracture in elderly men: prognostic factors and outcomes
DIAMOND, T. H., Thornley, S. W., Sekel, R., & Smerdely, P. (1997) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.1997.tb126646.x · Cited by 119
Self-citationPreventing osteoporosis: outcomes of the Australian Fracture Prevention Summit
Sambrook, P. N., Seeman, E., Phillips, S. R., & Ebeling, P. R. (2002) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2002.tb04475.x · Cited by 111
Changes in quantitative bone histomorphometry in aging healthy men
Clarke, B. L., Ebeling, P. R., Jones, J. D., Wahner, H. W., O’Fallon, W. M., Riggs, B. L., & Fitzpatrick, L. A. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.6.8964862 · Cited by 109
Preventing osteoporosis: outcomes of the Australian Fracture Prevention Summit
Carey, R. P. L., Plehwe, W. E., & Ebeling, P. R. (2002) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2002.tb04717.x · Cited by 94
Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss
Preston, D., Torréns, J. I., Harding, P., Howard, R. S., Duncan, W. E., & McLeod, D. G. R. (2002) · Prostate Cancer and Prostatic Diseases · doi:10.1038/sj.pcan.4500599 · Cited by 69
Zmuda, J. M., Cauley, J. A., Glynn, N. W., & Finkelstein, J. S. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.7.1417 · Cited by 66
Bruder, J., Ma, J. Z., Basler, J. W., & Welch, M. D. (2006) · Urology · doi:10.1016/j.urology.2005.07.017 · Cited by 61
Faulkner, K. G. (1998) · Journal of Clinical Densitometry · doi:10.1385/jcd:1:3:279 · Cited by 57
Men, bone and estrogen: unresolved issues
ORWOLL, E. S. (2003) · Osteoporosis International · doi:10.1007/s00198-002-1332-9 · Cited by 54
THE EPIDEMIOLOGY OF OSTEOPOROSIS
Dennison, E. M., & Cooper, C. C. (1996) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.1996.tb10015.x · Cited by 54
Background for studies on the treatment of male osteoporosis: state of the art
Kaufman, J., Johnell, O., Abadie, E., Adami, S., Audran, M., Avouac, B., Sedrine, W. B., Calvo, G., Devogelaer, J. P., Fuchs, V., et al. (2000) · Annals of the Rheumatic Diseases · doi:10.1136/ard.59.10.765 · Cited by 51
Hormone Therapy for Locally Advanced Prostate Cancer
Fowler, J. E., Bigler, S. A., White, P., & Duncan, W. L. (2002) · The Journal of Urology · doi:10.1016/s0022-5347(05)64676-9 · Cited by 49
Bisphosphonates in the Treatment of Bone Diseases
Delmas, P. D. (1996) · New England Journal of Medicine · doi:10.1056/nejm199612123352409 · Cited by 33
Androgen Deprivation in Veterans with Prostate Cancer: Implications for Skeletal Health
Wilcox, A., Carnes, M. L., Moon, T. D., Tobias, R., Baade, H., Stamos, E., & Elliott, M. E. (2006) · Annals of Pharmacotherapy · doi:10.1345/aph.1h209 · Cited by 30
Cited by
Risk of Fracture after Androgen Deprivation for Prostate Cancer
Shahinian, V. B., Kuo, Y.-F., Freeman, J. L., & Goodwin, J. S. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041943 · Cited by 1,375
Riding the Crest of the Teachable Moment: Promoting Long-Term Health After the Diagnosis of Cancer
Demark-Wahnefried, W., Aziz, N. M., Rowland, J. H., & Pinto, B. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.230 · Cited by 1,119
Androgen Deprivation Therapy for Prostate Cancer
Sharifi, N. (2005) · JAMA · doi:10.1001/jama.294.2.238 · Cited by 1,083
Review of Exercise Intervention Studies in Cancer Patients
Galvão, D. A., & Newton, R. U. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.085 · Cited by 578
Bone Loss after Initiation of Androgen Deprivation Therapy in Patients with Prostate Cancer
Greenspan, S. L., Coates, P., Sereika, S. M., Nelson, J. B., Trump, D. L., & Resnick, N. M. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0183 · Cited by 411
Metadata
- Authors
- Diamond, T. H., Higano, C. S., Smith, M. R., Guise, T. A., & Singer, F. R.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2004-01-19
- Volume
- 100
- Issue
- 5
- Pages
- 892-899
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2083492047
- Cited by
- 255
- References
- 53
- FWCI
- 26.64
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.